Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Clinical trial NCT01328106 · WITHDRAWN

Trial details

NCT number: NCT01328106
Sponsor: GlaxoSmithKline
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

GNA11 Mutation-positive Metastatic Melanoma GNAQ Mutation-positive Metastatic Melanoma Cancer Metastatic Uveal Melanoma

Start date: 2010-11-01
Primary completion: 2011-08-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.